Clinical Trial Update: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intravitreal ranibizumab injections to sham control in Central Retinal Vein Occlusion; the study has completed and results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Central Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2017-04-24